Farxiga Approval Expands Use to More Patients With Heart Failure
Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.
Diagnosis & Disease Information
Black Men With Metastatic Prostate Cancer More Frequently Refuse Chemotherapy
A recent study found a racial disparity in the use of guideline-concordant treatment for metastatic prostate cancer.
Risk of Death Markedly Affected by N-Terminal B-Type Natriuretic Peptide Change
A study was conducted to determine the relationship between changes in NT-proBNP levels and risk for heart failure and death.
Subclinical Valvular Heart Disease Increasingly Common Among Older Adults
Researchers sought to describe the prevalence of VHD stages among older adults; determine the prognostic relevance of VHD stages for incidence CVDs; and characterize the progression in VHD stages over 6 years in late life.
Kidney Biopsy Findings Predict Risk of Cardiovascular Events in CKD
Histologic lesions in the kidney may reflect systemic processes that lead to cardiovascular events, according to investigators.
Wearable Furosemide Delivery System Furoscix Now Available
Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for SC administration via an on-body infusor for outpatient self-administration.
Omecamtiv Mecarbil Denied Approval for Heart Failure
The FDA is requiring the Company to conduct an additional clinical trial evaluating omecamtiv mecarbil for HFrEF.
Empagliflozin Benefits Patients With Heart Failure and Preserved Ejection Fraction
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
AHA Statement on Complementary or Alternative Medicines for Heart Failure
The American Heart Association has issued a statement regarding HF patient’s use of over-the-counter medications and supplements.
Empagliflozin Gets Priority Review for Heart Failure Independent of LVEF
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
- Loading...
Loading...
Loading... 
Loading...